ATG-125 / Antengene - LARVOL DELTA

ATG-125, a novel B7H3 × PD-L1 bispecific antibody-drug conjugate, demonstrates potent antitumor efficacy by dual targeting of immune evasion and direct tumor killing (AACR 2026) - "Its unique mechanism combines enhanced, dual-target-mediated internalization for superior payload delivery with potential restoration of anti-tumor immunity. The compelling preclinical profile of ATG-125 underscores its significant therapeutic potential and supports its advancement into clinical trials for patients with solid tumors."

ADC • Bispecific • Clinical • IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD276 • CD69 • IFNG • IL2

The Company plans to submit an IND application for ATG-125 in the second quarter of 2027. (PRNewswire)

IND • Solid Tumor

Title: ATG-125, a novel B7H3 x PD-L1 bispecific antibody-drug conjugate, demonstrates potent antitumor efficacy by dual targeting of immune evasion and direct tumor killing (PRNewswire) - "Antengene to Present on...Preclinical Programs at AACR 2026....ATG-125 demonstrated strong binding to both B7-H3 and PD-L1 and efficient antigen-dependent internalization, enabling intracellular release of a topoisomerase I inhibitor payload. The molecule showed potent target-dependent cytotoxicity across multiple solid tumor cell lines and enhanced T-cell activation in immune assays. In xenograft models, ATG-125 induced marked tumor regression and demonstrated superior antitumor activity compared with single-target ADC comparators."

Preclinical • Oncology • Solid Tumor

ATG-125 (B7-H3 × PD-L1 bispecific ADC) (PRNewswire) - "Preclinical studies demonstrate that the bispecific ADC delivers superior in vivo efficacy compared with single-target B7-H3-ADC or PD-L1-ADC approaches. The Company plans to submit an IND for ATG-125 in Q1 2027."

IND • Preclinical • Oncology